I'm A Patient
I'm A Provider
Overview
Optometry clinics evaluating a device-based therapy for dry AMD can assess 6 dimensions: Regulatory approval status, the quality of published clinical evidence, patient eligibility criteria and how well they match the clinic’s AMD population, the defined treatment protocol, the post-market safety record and how the therapy integrates with the practice’s existing monitoring and co-management workflows.1
Adopting a device for clinical use is a professional and ethical commitment. The evidence standard required to recommend a treatment to patients should be at least as rigorous as a clinician would expect for any other intervention. Regulatory approval sets the minimum bar; published trial quality determines how confidently outcomes can be communicated to patients.2
Why Optometry Clinics Should Consider MacuMira
Optometrists are typically the primary point of contact for AMD patients throughout the course of their disease. They conduct routine monitoring to track disease progression, advise on supplementation and lifestyle, and co-manage with ophthalmologists when specialist input is deemed necessary. This ongoing relationship makes optometry clinics a natural setting for device-based therapy like MacuMira, which requires consistent monitoring and patient follow-up over time.3
Adding an authorized treatment device to an optometry practice’s AMD service also benefits patients who might otherwise have limited access to this therapy. Not every patient with dry AMD is under the active care of a retinal specialist or a large ophthalmology practice. Many are seen exclusively in community optometry, and for those patients, having device-based therapy like MacuMira available at their regular clinic helps remove an access barrier.1
Evaluation Framework for Optometry Clinics
1. Regulatory Authorization
Any device used in an optometry clinic for the management of dry AMD should hold regulatory authorization for that specific indication. In Canada, this means a Health Canada Medical Device Licence. In Australia, TGA registration on the ARTG for dry AMD. Verifying approval status should be considered a professional obligation, not an optional check.4
Approval for a related but distinct indication is not the same as authorization for dry AMD. A device cleared for a general ophthalmology purpose or a different eye condition has not been assessed for the specific claim being made when it is offered to dry AMD patients. Clinicians should ask the manufacturer for the specific regulatory licence number and confirm the indication it covers.
It is also worth confirming that the authorization is current. Regulatory licences can lapse or be modified, so a device that held approval at one point may not hold it today.
2. Published Clinical Evidence
The quality of clinical evidence behind a device determines how confidently a clinician can communicate expected outcomes to patients. The most robust evidence standard for a dry AMD device is a published peer-reviewed randomized controlled trial with a sham comparator, pre-specified primary endpoints and independent statistical analysis.2
A sham control can be particularly important in device trials. Patients who believe they are receiving an active treatment tend to report improvements in subjective symptoms regardless of whether the device is acting. A sham-controlled design separates the effect of the active therapy from this expectation effect, making the measured outcomes more reliable as a guide to what patients can actually expect.
Clinicians should read the primary trial publication rather than manufacturer-provided summaries. Summaries may present headline results without adequately reporting subgroup outcomes, secondary endpoints or adverse event data. The full publication provides the context needed to assess how applicable the evidence is to the specific patients a clinic sees.
MacuMira’s published randomized, sham-controlled trial showed that the treatment group improved significantly in both visual acuity and contrast sensitivity. The average gain was 8.2 letters on the ETDRS scale, with 48% of treated patients gaining 10 or more letters. Contrast sensitivity improved by an average of 0.24 log units. The trial recorded zero device-related serious adverse events, and more than 21,000 real-world treatments across 3 countries have occurred since launch.5
3. Patient Eligibility
The population studied in a device’s clinical trial defines the group for whom the evidence is most directly applicable. Clinicians recommending treatment to patients who differ substantially from the trial population are extrapolating rather than applying evidence directly. That is not always inappropriate, but it requires transparency with the patient about what is and is not known.2
For MacuMira, the published trial enrolled patients with dry AMD and best-corrected visual acuity between 20/50 and 20/200. Optometry clinics should assess their AMD patient population against this range when evaluating whether the device is a good fit. Patients with better baseline acuity than 20/50 may experience a ceiling effect that limits the measurable scope for improvement. The clinical conversation with those patients should reflect that nuance rather than presenting a uniform expected outcome.5
MacuMira is not indicated for patients with wet AMD. Optometrists who manage both dry and wet AMD patients should have a clear protocol for confirming AMD type before discussing MacuMira.
4. Treatment Protocol
A device with a clearly defined, published treatment protocol enables consistent delivery across clinicians and supports meaningful outcome tracking. The protocol should specify session frequency, session duration, electrode placement and the ongoing maintenance schedule required to sustain benefit over time.5
MacuMira’s treatment schedule involves approximately 7 visits in the first year followed by around 4 visits per year thereafter. This maintenance schedule reflects the ongoing nature of dry AMD and should be built into the informed consent process so patients understand what they are committing to before treatment begins. Patients who discontinue maintenance visits may not sustain the improvement achieved in the initial treatment period.5
From a practice management standpoint, the maintenance schedule also has implications for appointment capacity and patient scheduling. Clinics adopting device-based therapy should plan for ongoing appointments rather than treating the initial course as a one-time commitment.
5. Post-Market Safety Record
A strong post-market safety record across a large and geographically diverse patient population provides evidence that a device performs safely in real-world conditions, which differ from controlled trial environments in important ways. A trial population is typically selected, monitored closely and treated in controlled settings. Real-world use involves broader patient groups, variable clinical environments and longer follow-up periods.5
MacuMira’s post-market record includes more than 21,000 treatments delivered across hundreds of clinics in 3 countries with no device-related serious adverse events reported. For a relatively new device category, this real-world record adds meaningful confidence beyond the trial data alone. Clinicians evaluating any device should ask the manufacturer for post-market safety data including any adverse event reports submitted to regulatory authorities.5
6. Workflow Integration
MacuMira is designed to integrate into a comprehensive AMD management plan rather than be offered as a standalone service. Patients who begin therapy should continue regular OCT monitoring, AREDS2 supplementation where clinically indicated, and lifestyle counselling. The optometrist remains responsible for ongoing disease monitoring and for detecting any changes in AMD status, including signs of conversion from dry to wet AMD.1
Practically, adopting a device-based therapy like MacuMira strengthens rather than replaces the monitoring relationship. A patient receiving therapy will be seen more frequently than a patient on monitoring alone, which increases the opportunity to detect disease changes early.
Clinics should also consider how they will document outcomes over time. Tracking ETDRS visual acuity and contrast sensitivity at defined intervals allows the practice to assess whether individual patients are responding as expected and provides a basis for recommending continuation or adjustment of the treatment plan.
Informed Consent Considerations
Before beginning treatment, patients should understand what the therapy is designed to achieve, what the published evidence shows, the eligibility criteria, and the limitations. Specifically, patients should understand that the therapy is indicated to improve visual function and is not indicated for stopping AMD progression. They should understand that not all patients respond and that individual results vary. They should understand the maintenance schedule and the cost commitment involved. They should also understand that the therapy is not indicated for wet AMD.2
A clear, unhurried consent process that addresses these points protects both the patient and the clinician. Patients who have been accurately informed before treatment are better positioned to evaluate their own response and to make sensible decisions about continuing therapy.
Questions Optometry Clinics Should Ask Device Manufacturers
- What is the specific regulatory licence or registration number and what indication does it cover?4
- Can you provide the primary published trial paper rather than a summary document?2
- What are the defined patient eligibility criteria and are there contraindications I should be aware of for my patient population?
- What is the full treatment protocol, including the initial course, maintenance schedule, and recommended outcome monitoring intervals?5
- What post-market safety data is available and has any adverse event data been submitted to the relevant regulatory authority?5
- What training and clinical support does the manufacturer provide for clinicians and clinic staff?
- What outcome tracking tools or templates are available to support consistent documentation?
Conclusion
Optometry clinics evaluating a device-based therapy for dry AMD should apply a rigorous framework. This can include regulatory approval, published trial quality, patient eligibility fit, treatment protocol, post-market safety record, and workflow integration. MacuMira is an authorized device indicated to improve visual function in dry AMD patients, supported by a published randomized sham-controlled trial. Clinics should read the primary trial publication, independently verify regulatory status, and establish a clear informed consent and outcome-monitoring process before offering any device-based therapy.
Disclaimer
This article is for informational and educational purposes only. It does not constitute a clinical endorsement of any specific device and does not replace the professional judgment of a licensed optometrist. Clinicians should apply their own assessment of the evidence when making adoption and treatment decisions.
Glossary
MacuMira: An approved medical device indicated to improve visual function in patients with dry AMD, delivered via low-level electrical stimulation in a clinical setting under the supervision of a licensed eye care professional. Not indicated for wet AMD.
Health Canada Medical Device Licence: Regulatory authorization confirming a device meets Canadian safety and efficacy standards for its approved indication. Required for clinical use of any medical device in Canada.
TGA (Therapeutic Goods Administration): Australia’s regulatory authority for therapeutic goods. A device on the ARTG has been assessed for safety and efficacy for its approved indication.
ETDRS scale: The Early Treatment Diabetic Retinopathy Study visual acuity scale, scored letter by letter. The standard outcome measure in AMD clinical trials.
Contrast sensitivity: The ability to distinguish objects from their background at varying contrast levels. A key outcome measure in dry AMD trials alongside visual acuity.
Sham-controlled trial: A clinical trial in which the control group receives a treatment mimicking the active intervention in all observable ways except the active component. The appropriate comparator for device efficacy trials.
Ceiling effect: In clinical measurement, the limited room for improvement when a patient’s baseline function is near the upper end of the measurement scale.
Dry AMD: A progressive retinal condition affecting the macula. The most common form of AMD. Distinct from wet AMD in pathophysiology and clinical management.
Wet AMD: A form of AMD involving abnormal blood vessel growth beneath the retina. Treated with anti-VEGF injections. Not the same as dry AMD. Device-based therapy for dry AMD is not indicated for wet AMD.
AREDS2 formula: A nutritional supplement combination reducing progression risk to advanced AMD in eligible patients. Addresses structural progression rather than visual function improvement.
Post-market surveillance: Ongoing monitoring of a device’s safety and performance after regulatory approval through adverse event reporting and real-world outcome tracking.
References
1. Age-Related Macular Degeneration. National Eye Institute, National Institutes of Health. Last reviewed November 2023. Accessed June 2026. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration.
2. Understanding Macular Degeneration. American Academy of Ophthalmology. Published November 2025. Accessed June 2026. https://www.aao.org/eye-health/diseases/amd-macular-degeneration.
3. Age-Related Macular Degeneration (AMD). Canadian Ophthalmological Society. Date not listed. Accessed June 2026. https://www.seethepossibilities.ca/eye-health/age-related-macular-degeneration/.
4. Medical Device Licences. Health Canada. Date not listed. Accessed June 2026. https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/licences.html.
5. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Parkinson KM, Sayre EC, Tobe SW. International Journal of Retina and Vitreous. Published May 2023. Accessed June 2026. https://macumira.com/wp-content/uploads/2025/07/MacuMira-Clinical-Trial.pdf.
